Investments, Funding & Disinvestment

The platform offers a comprehensive suite of tools, including a library of AI models, advanced analytics packages, and an AI-powered agent that assists researchers in designing experiments.

CrossBridge Bio plans to submit an Investigational New Drug (IND) application for CBB-120, positioning the candidate for clinical development.

The collaboration leverages JW Pharmaceutical’s established research and development capabilities to accelerate the drug’s entry into South Korea’s growing metabolic disease sector.

Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.

The company receives USD10 million in near-term milestones and stands to earn up to USD 705 million additional milestone payments upon reaching key development and regulatory benchmarks.

The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.

Varipulse Pro will receive prominent visibility at the European Heart Rhythm Association (EHRA) annual meeting, where J&J plans to conduct live procedure demonstrations and offer practical training sessions for healthcare professionals.

Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners co-led the financing initiative.

The government has set a bold target: by 2030, Egypt will manufacture 140 million human vaccine doses per year.

Both nations will work together to strengthen their health information systems through coordinated collection, analysis, and sharing of epidemiological data, scientific research findings, and public health intelligence.